The latest new contracts, like Silexion Therapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Silexion Therapeutics Corp. has announced its ongoing collaboration with Evonik, a global leader in specialty chemicals, for the development of an advanced siRNA formulation aimed at enhancing cancer treatment efficacy. The collaboration aims to create a sustained-release formulation that enhances the stability and targeting of SIL-204, for the treatment of KRAS-driven cancers.
Company Information
Company
Silexion Therapeutics
Location
Ramat Gan, Tel Aviv District, Israel
About
Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
Ramat GanBiotechnologyHealth CareTherapeuticsPharmaceutical